Drug intelligence / Profile preview

fruquintinib + everolimus

Development stage: Unknown
Lead developer: Hutchison Medipharma
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of fruquintinib and everolimus. Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3, designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage. Everolimus is an mTOR inhibitor. While both drugs have been studied separately in renal cell carcinoma (RCC), there is limited information about their use as a specific combination therapy.

Targets

Mechanistic target of rapamycin complex 1VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)

Beyond the preview

Go deeper on fruquintinib + everolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fruquintinib + everolimus.

Explore the full profile